X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BBI-825 is an ecDNA-directed therapy (ecDTx), a novel, selective, oral small molecule inhibitor of ribonucleotide reductase (RNR), it is being investigated in patients with locally advanced or metastatic cancer with resistance gene amplifications.
Lead Product(s): BBI-825
Therapeutic Area: Oncology Product Name: BBI-825
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
The net proceeds will be used to fund the company's ecDNA-directed therapy (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) and is being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. research and development
Lead Product(s): BBI-355
Therapeutic Area: Oncology Product Name: BBI-355
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 27, 2024
Details:
Under the collaboration, Eli Lilly will supply CDK4/6 inhibitor Verzenio (abemaciclib) for use in combination with BBI-355, an oral, selective small molecule inhibitor of CHK1, in a clinical trial for locally advanced or metastatic solid tumors with oncogene amplifications.
Lead Product(s): BBI-355,Abemaciclib
Therapeutic Area: Oncology Product Name: BBI-355
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 19, 2023
Details:
Under the agreement, Taiho will provide futibatinib for Boundless Bio’s ongoing Phase 1/2 clinical trial, which will assess BBI-355 in combination with certain selected targeted therapies, including futibatinib, in patients with specific oncogene amplified solid tumors.
Lead Product(s): BBI-355,Futibatinib
Therapeutic Area: Oncology Product Name: BBI-355
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiho Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 18, 2023
Details:
Boundless Bio will use the financing to advance BBI-355, a potentially best-in-class checkpoint kinase 1 inhibitor and the first ecDNA-directed therapy, through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers.
Lead Product(s): ecDNA-directed Therapy
Therapeutic Area: Oncology Product Name: BBI-355
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Leaps by Bayer
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 16, 2023
Details:
BBI-355 is a potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor and the first extrachromosomal DNA (ecDNA)-directed therapy (ecDTx) designed to treat patients with oncogene amplified cancers.
Lead Product(s): BBI-355
Therapeutic Area: Oncology Product Name: BBI-355
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes companion diagnostic and expand its pipeline of novel cancer therapies targeting ecDNA.
Lead Product(s): ecDNA-directed therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Nextech Invest
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
